*Freedom of Information Act Considerations:* Public comments submitted for this planning effort, including names and street addresses of respondents, will be available for public review at the Anchorage Field Office during regular business hours (7:30 a.m. to 4 p.m.), Monday through Friday, except holidays. All submissions from organizations or businesses, and from individuals identifying themselves as representatives or officials of organizations or businesses, will be made available for public inspection in their entirety. Individual respondents may request confidentiality. If you wish to withhold your name or address from public review or from disclosure under the Freedom of Information Act, you must state this prominently at the beginning of your comments. Such requests will be honored to the extent allowed by law.

**June Bailey,**

*Field Office Manager.*

[FR Doc. 04–26725 Filed 12–3–04; 8:45 am]

**BILLING CODE 4310–$$–P**

## DEPARTMENT OF JUSTICE

### Office of Justice Programs

**[OJP (OVW) Docket No. 1414]**

### Notice of Cancellation of Meeting

**AGENCY:** Office on Violence Against Women, DOJ.

**ACTION:** Notice of cancellation of meeting.

**SUMMARY:** This notice cancels the public meeting of the National Advisory Committee on Violence Against Women scheduled for December 7, 2004, from 8:30 a.m. to 4 p.m.

**DATES:** The cancelled meeting was scheduled to take place on December 7, 2004, from 8:30 a.m. to 4 p.m.

**FOR FURTHER INFORMATION CONTACT:** Jana Sinclair White, The National Advisory Committee on Violence Against Women, 810 Seventh Street, NW., Washington, DC, 20531; by telephone at: (202) 353–4343; e-mail: *Jana.S.White@usdoj.gov;* or fax: (202) 307–3911. You may also view the Committee's Web site at: *http://www.ojp.usdoj.gov/vawo/nac/welcome.html.*

Dated: November 30, 2004.

**Margaret Davis,**

*Principal Deputy Director, Office on Violence Against Women.*

[FR Doc. 04–26683 Filed 12–3–04; 8:45 am]

**BILLING CODE 4410–18–P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

### Manufacturer of Controlled Substances; Notice of Application; Correction

By Notice dated June 28, 2004, and published in the **Federal Register** on July 13, 2004, (69 FR 42067–42068), dated April 29 2004, the listing of controlled substances for Oxycodone (9143) and Hydrocodone (9193), were inadvertently omitted, by Cedarburg Pharmaceuticals, Inc., 870 Badger Circle, Grafton, Wisconsin 53024.

Dated: November 22, 2004.

**William J. Walker,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 04–26734 Filed 12–3–04; 8:45 am]

**BILLING CODE 4410–09–P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

### Importation of Controlled Substances; Notice of Application

Pursuant to 21 U.S.C. 958(1)), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a registration under 21 U.S.C. 952 (a)(2)(b) authorizing the importation of such substances, provide manufacturers holding registrations for the bulk manufacture of the substances an opportunity for a hearing.

Therefore, in accordance with 21 CFR 1301.34(a), this is notice that on September 20, 2004, Johnson Matthey Inc., Pharmaceutical Materials, 2003 Nolte Drive, West Deptford, New Jersey 08066, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of the basic classes of controlled substances:

| Drug | Schedule |
|---|---|
| Phenylacetone (8501) | II |
| Raw Opium (9600) | II |
| Concentrate of Poppy Straw (9670). | II |

The company plans to import the listed controlled substances as raw materials for use in the manufacture of bulk controlled substances for distribution to its customers.

Any manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file written comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47.

Any such comments or objections or requests for hearing may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA **Federal Register** Representative, Office of Liaison and Policy (ODLR) and must be filed no later than January 5, 2005.

This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the **Federal Register** on September 23, 1975, (40 FR 43745–46), all applicants for registration to import basic class of any controlled substance in Schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

Dated: November 22, 2004.

**William J. Walker,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 04–26735 Filed 12–3–04; 8:45 am]

**BILLING CODE 4410–09–P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

### Manufacturer of Controlled Substances; Notice of Application

Pursuant to section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on September 20, 2004, Johnson Matthey, Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, New Jersey 08066, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed:

| Drug | Schedule |
|---|---|
| Tetrahydrocannabinols (7370) | I |
| Difenoxin (9168) | I |
| Propiram (9649) | I |
| Amphetamine (1100) | II |
| Methylphenidate (1724) | II |

| Drug | Schedule |
|---|---|
| Codeine (9050) | II |
| Oxycodone (9143) | II |
| Hydromorphone (9150) | II |
| Hydrocodone (9193) | II |
| Morphine (9300) | II |
| Thebaine (9333) | II |
| Alfentanil (9737) | II |
| Sufentanil (9740) | II |
| Fentanyl (9801) | II |

The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative, Office of Liaison and Policy (ODLR) and must be filed no later than February 4, 2005.

Dated: November 22, 2004.

**William J. Walker,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 04–26736 Filed 12–3–04; 8:45 am]

**BILLING CODE 4410–01–P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

### Manufacturer of Controlled Substances; Notice of Application

Pursuant to section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on August 19, 2004, Organichem, Corporation, 33 Riverside Avenue, Rensselaer, New York 12144, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed:

| Drug | Schedule |
|---|---|
| Tetrahydrocannabinols (7370) | I |
| Amphetamine (1100) | II |
| Methylphenidate (1724) | II |
| Pentobarbital (2270) | II |
| Meperidine (9230) | II |
| Dextropoxyphene (9273) | II |

The company plans to manufacture bulk controlled substances for use internally and for distribution to its customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative, Office of Liaison and Policy (ODLR) and must be filed no later than February 4, 2005.

Dated: November 22, 2004.

**William J. Walker,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 04–26737 Filed 12–3–04; 8:45 am]

**BILLING CODE 4410–09–P**

## NATIONAL SCIENCE FOUNDATION

### Notice of Permit Applications Received Under the Antarctic Conservation Act of 1978 (Pub. L. 95–541)

**AGENCY:** National Science Foundation.

**ACTION:** Notice of Permit Applications Received under the Antarctic Conservation Act of 1978, Pub. L. 95–541.

**SUMMARY:** The National Science Foundation (NSF) is required to publish notice of permit applications received to conduct activities regulated under the Antarctic Conservation Act of 1978. NSF has published regulations under the Antarctic Conservation Act at Title 45 part 670 of the Code of Federal Regulations. This is the required notice of permit applications received.

**DATES:** Interested parties are invited to submit written data, comments, or views with respect to this permit application by January 5, 2005. This application may be inspected by interested parties at the Permit Office, address below.

**ADDRESSES:** Comments should be addressed to Permit Office, Room 755, Office of Polar Programs, National Science Foundation, 4201 Wilson Boulevard, Arlington, Virginia 22230.

**FOR FURTHER INFORMATION CONTACT:** Nadene G. Kennedy at the above address or (703) 292–7405.

**SUPPLEMENTARY INFORMATION:** The National Science Foundation, as directed by the Antarctic Conservation Act of 1978 (Pub. L. 95–541), as amended by the Antarctic Science, Tourism and Conservation Act of 1996, has developed regulations for the establishment of a permit system for various activities in Antarctica and designation of certain animals and certain geographic areas a requiring special protection. The regulations establish such a permit system to designate Antarctic Specially Protected Areas.

The applications received are as follows:

1. *Applicant:* Permit Application No. 2005–017, Peter Doran Earth and Environmental Sciences (MC186), University of Illinois at Chicago, Chicago, IL 60607.

**Activity for Which Permit Is Requested**

Take. The applicant plans to collect bone samples from mummified penguins and seals located on the ice surface of the Dry Valley lakes. The radiocarbon dates of the bones may help to determine the age of the lake ice covers.

**Location**

Taylor Valley Lakes.

**Dates**

December 1, 2004 to February 15, 2005.

**Nadene G. Kennedy,**

*Permit Officer, Office of Polar Programs.*

[FR Doc. 04–26675 Filed 12–3–04; 8:45 am]

**BILLING CODE 7555–01–M**

## NUCLEAR REGULATORY COMMISSION

**[Docket Nos. 50–325 and 50–324]**

### Carolina Power & Light Company, Brunswick Steam Electric Plant, Units 1 and 2; Notice of Acceptance for Docketing of the Application and Notice of Opportunity for Hearing Regarding Renewal of Facility Operating License Nos. DPR–71 and DPR–62 for an Additional 20-Year Period

The U.S. Nuclear Regulatory Commission (NRC or Commission) is considering an application for the renewal of Operating License Nos. DPR–71 and DPR–62, which authorizes the Carolina Power & Light Company, now doing business as Progress Energy Carolinas, Inc. (PEC), to operate Brunswick Steam Electric Plant, at 2,923 megawatts thermal for Unit 1, and 2,923 megawatts thermal for Unit 2. The renewed licenses would authorize the applicant to operate the Brunswick Steam Electric Plant, Units 1 and 2, for an additional 20 years beyond the period specified in the current licenses.